Publication: Receipt of Statins Is Associated With Lower Risk of Multiple Myeloma: Systematic Review and Meta-analysis
| dc.contributor.author | Ben Ponvilawan | en_US |
| dc.contributor.author | Nipith Charoenngam | en_US |
| dc.contributor.author | Thanitsara Rittiphairoj | en_US |
| dc.contributor.author | Patompong Ungprasert | en_US |
| dc.contributor.other | Faculty of Medicine, Siriraj Hospital, Mahidol University | en_US |
| dc.contributor.other | Johns Hopkins Bloomberg School of Public Health | en_US |
| dc.date.accessioned | 2020-05-05T05:07:04Z | |
| dc.date.available | 2020-05-05T05:07:04Z | |
| dc.date.issued | 2020-01-01 | en_US |
| dc.description.abstract | © 2020 Elsevier Inc. Data on receipt of statins and risk of multiple myeloma (MM) are still conflicting. We performed a systematic review that comprised terms for “statin” and “multiple myeloma” and identified 10 eligible studies for meta-analysis. The risk of MM was significantly lower among statin recipients than those who did not receive statins. | en_US |
| dc.identifier.citation | Clinical Lymphoma, Myeloma and Leukemia. (2020) | en_US |
| dc.identifier.doi | 10.1016/j.clml.2020.02.011 | en_US |
| dc.identifier.issn | 21522669 | en_US |
| dc.identifier.issn | 21522650 | en_US |
| dc.identifier.other | 2-s2.0-85081952857 | en_US |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/54484 | |
| dc.rights | Mahidol University | en_US |
| dc.rights.holder | SCOPUS | en_US |
| dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85081952857&origin=inward | en_US |
| dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
| dc.subject | Medicine | en_US |
| dc.title | Receipt of Statins Is Associated With Lower Risk of Multiple Myeloma: Systematic Review and Meta-analysis | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85081952857&origin=inward | en_US |
